<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="767">
  <stage>Registered</stage>
  <submitdate>20/09/2005</submitdate>
  <approvaldate>19/10/2005</approvaldate>
  <actrnumber>ACTRN12605000658617</actrnumber>
  <trial_identification>
    <studytitle>Vitamin D Intervention To Prevent Falls and Fractures and To Promote Mental Well-Being.</studytitle>
    <scientifictitle>Primary Care Prevention of Falls and Fractures in the Elderly by Annual Vitamin D Supplementation.</scientifictitle>
    <utrn />
    <trialacronym>Vital D Study</trialacronym>
    <secondaryid>National Health and Medical Research Council (NHMRC): NHMRC 251682</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Osteoporosis and fractures</healthcondition>
    <healthcondition>Mental well-being</healthcondition>
    <healthcondition>Falls prevention</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoporosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Fractures</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A Double-Blind Randomised Placebo-Controlled Vitamin D InterventionTrial in which 2,300 women at high risk of fracture are randomised to receive treatment (500,000 IU ergocalciferol orally) or placebo every Autumn/Winter for three to five consecutive years.  Participants are asked to complete a diary to record any falls and fractures.  This information is collected monthly and confirmed.  Participants also complete a validated mental well-being questionnaire at several timepoints throughout the study A subset of 126 women randomly selected undergo more intensive testing throughout the project.  At regular intervals these women undergo basic clinical anthropometry, balance and muscle strength assessment; questionnaires to assess mental well-being and pathology testing.</interventions>
    <comparator>Placebo</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Reduction in fracture rate [KERRIE SANDERS] between active and placebo arms</outcome>
      <timepoint>At completion of study.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Time to 'fracture' comparison between the groups (Kaplein-Mier analysis).</outcome>
      <timepoint>At completion of study.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The study involves ongoing continuous ascertainment of falls and fractures sustained by participants.</outcome>
      <timepoint>This will be analysed at the completion of the study in 2008. The substudy tests are measured at baseline, one year and five-years with results analysed for differences in change from baseline between placebo and active arm groups.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria />
    <inclusiveminage>70</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>All participants have unique study number.  These numbers are randomised to active or placebo arm of the study by department statistician using Minitab 11 software.  Randomisation of numbers is given to clinicial trials pharmacist</concealment>
    <sequence>Participants are assigned next study number upon study team having both their signed consent form and baseline serum calcium results within normal range.  These numbers are randomised to active or placebo arm of the study by department statistician using Minitab 11 software.  Randomisation of numbers is given to clinicial trials pharmacist.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>24/02/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>2300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>The University of Melbourne</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC project</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Commonwealth Dept of Health and Ageing</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Barwon Health</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study hypothesis is that an annual high dose (500,000 IU) of vitamin D2 will reduce the rate of falls and fracture compared with placebo in older women.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Barwon Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Geelong</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Kerrie Sanders</name>
      <address>Department of Clinical and Biomedical Sciences
The University of Melbourne
Barwon Health
PO Box 281
Geelong VIC 3220</address>
      <phone>+61 3 52267834</phone>
      <fax>+61 3 52267019</fax>
      <email>kerrie@barwonhealth.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Kerrie Sanders</name>
      <address>Department of Clinical and Biomedical Sciences
The University of Melbourne
Barwon Health
PO Box 281
Geelong VIC 3220</address>
      <phone>+61 3 52267834</phone>
      <fax>+61 3 52267019</fax>
      <email>kerrie@barwonhealth.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>